ArticleNature2020
Structural basis for the action of the drug trametinib at KSR-bound MEK.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.
0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 165 citations in OpenAlex.
- Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.Breast cancer research and treatment · 2025Trial
- Monovalent Nondegrading Molecular Glues: An Updated Overview of Emerging Mechanisms and Therapeutic Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies.Nature reviews. Drug discovery · 2026Review
- Protocol for Measuring Drug-Target Engagement in Mouse Colorectal Cancer Organoids Using NanoBRET Assay.Bio-protocol · 2026Article
- Mitochondrial gene expression-based model for the prediction of thyroid cancer prognosis.Endocrine connections · 2026Article
- Genistein from Thai Fermented Soybean (Thua-nao) Attenuates Osteoarthritis Pathogenesis via Dual Inhibition of NF-κB and MAPK Signaling: Evidence from Ex Vivo, Computational, and In Vitro Models.Journal of agricultural and food chemistry · 2026Article
- Advances in BRET probes for intracellular target engagement studies.Nature chemical biology · 2026Review
- MAPK Pathway Inhibition Reshapes Kinase Chemical Probe Reactivity Reflecting Cellular Activation States.ACS bio & med chem Au · 2026Article
- Dual RAF inhibition outperforms RAF-MEK combinations for suppressing ERK signaling in KRAS mutant cells.NPJ systems biology and applications · 2026Article
- Halogen-Containing Drugs in 2025: A Record Year for the Therapeutic Use and Synthesis of FDA-Approved Small Molecules.Biomolecules · 2026Review
- Induced proximity-based therapeutic modalities.Nature reviews. Drug discovery · 2026Review
- DeepDrugs: a mechanism-aware tri-linear attention framework for synergistic drug-combination prediction.Briefings in bioinformatics · 2026Article
- MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASPediatric blood & cancer · 2026Article
- Article
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer.Cell death discovery · 2026Review
- A molecular glue halts RAS-MAPK signaling.Nature cancer · 2026Article
- Combination Cancer Therapy and Reference Models for Assessing Drug Synergy in Glioblastoma.Current oncology (Toronto, Ont.) · 2025Review
- RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor.bioRxiv : the preprint server for biology · 2025Article
- Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma.Molecular cancer therapeutics · 2025Article
- BET proteins mediate survival mechanisms in human schwannoma model cells challenged with trametinib but not brigatinib.Oncogene · 2025Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Zaigham M Khan *Department of Oncological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-2471-4054
Alexander M Real *Department of Oncological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
William M Marsiglia *Department of Oncological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Arthur ChowDepartment of Oncological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mary E DuffyDepartment of Oncological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jayasudhan R YeraboluDepartment of Oncological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Alex P ScoptonDepartment of Oncological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Arvin C DarDepartment of Oncological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. arvin.dar@mssm.edu.ORCID http://orcid.org/0000-0003-0318-4848
Tisch Hospital · US
Funding
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Deanna L Benson · 2015 to 2026
$35.4MTRAINING PROGRAM IN CANCER THERAPYT32CA078207 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI James J Manfredi · 1999 to 2026
$11.6MA New Disease Platform Leveraging Complex Drosophila and Mammalian ModelsU54OD020353 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAGAN, ROSS LEIGH · 2015 to 2019
$10.3MTeaching biomedical and pharmacological trainees to produce FAIR data for AI & ML applicationsT32GM062754 · NIGMS · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SCHLESSINGER, AVNER · 2001 to 2023
$6.2MTargeting Oncogenic Ras-MAPK Signaling Complexes via the Scaffold KSRR01CA227636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Arvin Dar · 2018 to 2026
$4.0MTargeting Ras-Dependent Cancers with a Chemical Switch for an Inactive KinaseDP2CA186570 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DAR, ARVIN · 2013 to 2017
$2.7MDefining the relationship between kinase inhibitor pharmacophores and pro-/anti-targets using in vivo models of colorectal cancerK00CA212474 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MARSIGLIA, WILLIAM M · 2019 to 2022
$374kGenetic and Pharmacological Manipulation of KSR in KRAS-driven CancerF30CA232454 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI REAL, ALEXANDER · 2018 to 2021
$189kMechanisms of resistance and activation conferred by kinases displaying hinge and gate-keeper mutationsF99CA212474 · NCI · NEW YORK UNIVERSITY · PI MARSIGLIA, WILLIAM M · 2016 to 2017
$89kNCI NIH HHS DP2 CA186570NCI NIH HHS F30 CA232454NCI NIH HHS F99 CA212474NCI NIH HHS K00 CA212474NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA227636NCI NIH HHS T32 CA078207NIGMS NIH HHS T32 GM062754NIH HHS 5U54OD020353NIH HHS U54 OD020353
Abstract
The MAPK/ERK kinase MEK is a shared effector of the frequent cancer drivers KRAS and BRAF that has long been pursued as a drug target in oncology
Indexed as
Amino Acid SequenceAnimalsBinding SitesHumansMiceMitogen-Activated Protein Kinase KinasesModels, MolecularProtein BindingProtein Kinase InhibitorsProtein KinasesPyridonesPyrimidinonesraf KinasesSubstrate SpecificityKSR-1 protein kinaseMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProtein KinasesPyridonesPyrimidinonesraf Kinasestrametinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.